BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simpson WG, Heys SD, Whiting PH, Eremin O, Broom J. Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol 1995;99:143-7. [PMID: 7531626 DOI: 10.1111/j.1365-2249.1995.tb05524.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Nozoe T, Mori E, Takahashi I, Ezaki T. Preoperative elevation of serum C-reactive protein as an independent prognostic indicator of colorectal carcinoma. Surg Today. 2008;38:597-602. [PMID: 18612783 DOI: 10.1007/s00595-007-3680-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
2 Rossi L, Martin B, Hortin G, White R, Foster M, Moharram R, Stroncek D, Wang E, Marincola F, Panelli M. Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 2006;6:709-20. [DOI: 10.1002/pmic.200500004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
3 Wolbink GJ, Schalkwijk C, Baars JW, Wagstaff J, van den Bosch H, Hack CE. Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother 1995;41:287-92. [PMID: 8536274 DOI: 10.1007/BF01517216] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
4 Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol. 2000;23:263-266. [PMID: 10857890 DOI: 10.1097/00000421-200006000-00011] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 3.7] [Reference Citation Analysis]
5 Shaker MA, Younes HM. Interleukin-2: Evaluation of Routes of Administration and Current Delivery Systems in Cancer Therapy. Journal of Pharmaceutical Sciences 2009;98:2268-98. [DOI: 10.1002/jps.21596] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
6 Li Y, Krowka MJ, Qi Y, Katzmann JA, Song Y, Li Y, Mandrekar SJ, Yang P. Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival. J Thorac Oncol 2011;6:291-5. [PMID: 21173712 DOI: 10.1097/JTO.0b013e31820213fb] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
7 Huang H, Campbell SC, Nelius T, Bedford DF, Veliceasa D, Bouck NP, Volpert OV. α1-antitrypsin inhibits angiogenesis and tumor growth. Int J Cancer 2004;112:1042-8. [DOI: 10.1002/ijc.20494] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
8 Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One 2015;10:e0143080. [PMID: 26717416 DOI: 10.1371/journal.pone.0143080] [Cited by in Crossref: 113] [Cited by in F6Publishing: 116] [Article Influence: 18.8] [Reference Citation Analysis]
9 Faust D, Raschke K, Hormann S, Milovic V, Stein J. Regulation of alpha1-proteinase inhibitor release by proinflammatory cytokines in human intestinal epithelial cells. Clin Exp Immunol 2002;128:279-84. [PMID: 11985518 DOI: 10.1046/j.1365-2249.2002.01843.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
10 Perincek G, Avcı S. Evaluation of alpha-1-antitrypsin levels in blood serum of patients with chronic obstructive pulmonary disease. Acta Biomed 2018;90:37-43. [PMID: 30889153 DOI: 10.23750/abm.v90i1.6780] [Reference Citation Analysis]
11 Sebzda T, Gnus J, Dziadkowiec B, Latka M, Gburek J. Diagnostic usefulness of selected proteases and acute phase factors in patients with colorectal adenocarcinoma. World J Gastroenterol 2021; 27(39): 6673-6688 [DOI: 10.3748/wjg.v27.i39.6673] [Reference Citation Analysis]
12 Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, Schmidinger M. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006;95:691-698. [PMID: 16940978 DOI: 10.1038/sj.bjc.6603327] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 5.1] [Reference Citation Analysis]
13 Heys SD. Evolution of breast cancer management: Focus on neoadjuvant chemotherapy. Breast Cancer 2001;8:339-50. [DOI: 10.1007/bf02967535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Fridman WH, Tartour E. Cytokines and cell regulation. Mol Aspects Med 1997;18:3-90. [PMID: 9100222 DOI: 10.1016/s0098-2997(96)00012-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Gough DB, Heys SD, Eremin O. II—Cancer cachexia: treatment strategies. European Journal of Surgical Oncology (EJSO) 1996;22:286-91. [DOI: 10.1016/s0748-7983(96)80020-5] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
16 Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. The Lancet Oncology 2003;4:224-32. [DOI: 10.1016/s1470-2045(03)01034-9] [Cited by in Crossref: 151] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
17 Glojnarić I, Casl MT, Simić D, Lukac J. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 2001;39:129-33. [PMID: 11341746 DOI: 10.1515/CCLM.2001.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
18 Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176:335-338. [PMID: 9817250 DOI: 10.1016/s0002-9610(98)00204-9] [Cited by in Crossref: 158] [Cited by in F6Publishing: 67] [Article Influence: 6.9] [Reference Citation Analysis]
19 Nazarov PG. Reaction of C-reactive protein with interleukin-2 receptor α-Chain. Bull Exp Biol Med 1998;125:582-4. [DOI: 10.1007/bf02445246] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
20 Kedar I, Mermershtain W, Ivgi H. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer 2004;110:260-5. [PMID: 15069691 DOI: 10.1002/ijc.20089] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
21 Tartour E, Fridman WH. Cytokines and cancer. Int Rev Immunol. 1998;16:683-704. [PMID: 9646182 DOI: 10.3109/08830189809043014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 1.4] [Reference Citation Analysis]